Serum TA90 immune complex assay can predict outcome after resection of thick (≥4 mm) primary melanoma and sentinel lymphadenectomy

Annals of Surgical Oncology

Volumn 9, Issue 2, 2002, Pages 120-126

  Chung, Mathew H ^a   Gupta, Rishab K ^a   Essner, Richard ^a   Ye, Wei ^a   Yee, Reynold ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Immune assay; Primary melanoma; TA90 immune complex; Tumor associated antigen

Indexed keywords

CANCER ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CALIFORNIA; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 0036201970     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/aso.2002.9.2.120     Document Type: Article

References (24)

1. The role of elective lymph node dissection in melanoma: Rationale, results, and controversies
2. Letter to the editor
3. Prognosis of thick cutaneous melanoma of the trunk and extremity
4. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (≥4 mm) primary melanoma
5. Current status of intraoperative lymphatic mapping and sentinel lymphadenectomy for melanoma: Is it standard of care?
6. Prognosis of thick cutaneous melanoma
7. Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy
8. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
9. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients
10. Characterization of a 90-100 kDa tumor-associated antigen in the sera of melanoma patients
11. Circulating immune complexes in malignant melanoma
12. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma
13. Tumor-associated antigen TA90 immune complex assay predicts recurrence and survival after surgical treatment of stage I-III melanoma
14. Technical details of intraoperative lymphatic mapping for early stage melanoma
15. Standardized probe-directed sentinel node dissection in melanoma
16. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma
17. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: An immunologic survival model
18. Prognostic factors in 1,521 melanoma patients with distant metastasis
19. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay
20. Molecular staging of malignant melanoma: Correlation with clinical outcome
21. Clinical relevance of molecular staging for melanoma
22. Evaluation of melanin-related metabolites as markers of melanoma progression
23. Evaluation of new putative tumor markers for melanoma
24. Role of computed tomography in the staging of primary melanoma